ClinicalTrials.gg
RecruitingNCT06035029Updated Sep 13, 2023

Intestinal Flora and Metabonomics of Appendicitis

An observational study in Appendicitis, Intestinal Metaplasia and Metabonomics, sponsored by HongyiQu. Recruiting at 1 site in China. Open to participants aged 1 Year to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by HongyiQu · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
1 Year to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Appendicitis with a site in China — 6 open to participants now, 7 under way, none of them phase 3. Appendicitis · China.

Started
2023
with 1 other
Observational
4 of 17
3 open now
Registered
11th of 17
by date
Lead sponsor
1 of 17
HongyiQu

Among the 17 studies in Appendicitis with a site in China, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 11th registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

6 of the 17 studies in Appendicitis with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 1 Year to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Appendicitis with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the key bacterial flora and metabolites associated with appendicitis in children. The main questions it aims to answer are:

  • To screen out the key biomarkers of pediatric appendicitis.
  • What are the microbial differences in different parts of pediatric appendicitis patients.

Participants will detect feces using 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology and differences of the fecal metabolites between healthy children and appendicitis children were analyzed using untargeted metabolomics based on Liquid chromatography-tandem mass spectrometry(LC-M S/MS) platform.Through the analysis of intestinal bacterial flora and metabolomics association and the differential analysis of intestinal bacterial flora in different parts of the case group, the key bacterial flora and metabolites were excavated.

Read the detailed description

Participants will detect feces using 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology and differences of the fecal metabolites between healthy children and appendicitis children were analyzed using untargeted metabolomics based on Liquid chromatography-tandem mass spectrometry(LC-M S/MS) platform.

Differences in the intestinal flora of different parts of the case group: the intestinal flora of the case group in feces and rectum were detected by 16s ribosomal RiboNucleicAcid (16S rRNA) gene sequencing technology, and the intestinal flora of different parts were analyzed and compared.

Through the analysis of intestinal bacterial flora and metabolomics association and the differential analysis of intestinal bacterial flora in different parts of the case group, the key bacterial flora and metabolites were excavated.

03

Conditions studied

  • Appendicitis
  • Intestinal Metaplasia
  • Metabonomics

Browse trials for

04

Who can participate

Ages eligible
1 Year to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children aged 1-14 in Department of Pediatric Surgery in Shandong Qianfoshan Hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 1-14 years who were initially diagnosed with appendicitis and underwent laparoscopic appendectomy
  • Children aged 1-14 years with non-digestive tract disease and no history of digestive tract disease

Exclusion criteria

Exclusion Criteria:

  • A family history of intestinal disease
  • Allergic to antibiotic therapy drugs
  • Patients with long-term drug use causing microbial structure changes or intestinal flora disorders
  • Patients with other congenital diseases such as Meckel's diverticulum, intestinal rotation and other malrotation
  • With other systemic diseases, such as obvious upper respiratory tract infection or myocarditis
  • Children with other digestive system diseases after auxiliary examination or surgical diagnosis
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Case group

    Children with appendectomy for appendicitis

  • Control group

    Children with no digestive disease or medical history

06

What researchers measure

Primary outcomes

  1. The 16S rRNA gene sequence

    Samples were qualified for Polymerase Chain Reaction(PCR) amplification of the V3 and V4 variable regions of the 16 rRNA gene. The Polymerase Chain Reaction(PCR) products were then quantified by confirming the presence of PCR amplicons by gel electrophoresis on a 2% agarose gel and staining with ethidium bromide, and equimolar amounts (100 ng) of PCR amplicons were pooled prior to pyrosequencing. High-throughput sequencing of the qualified 16S amplicon libraries.

    Time frame: up to 24 weeks

  2. Fecal untargeted metabolomics testing

    To analyze the fecal metabolite differences and the correlation of appendicitis and metabolites using untargeted metabolomics based on the LC-M S/MS platform. To screen key metabolites in pediatric appendicitis.

    Time frame: up to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2025, 21 months after the start.

Of 54 non-industry observational studies under Appendicitis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 56. This study's planned 21 months is close to that.

Counting every sponsor, half of 56 studies reached it within 23 months; a quarter within 7 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 13, 2023
StartActual
Apr 3, 2023
Primary completionEst.
Jan 2025
CompletionEst.
Jul 2025
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06035029
Lead sponsor
HongyiQu
Responsible party
HongyiQu (professor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Sep 13, 2023
Start date
Apr 3, 2023
Primary completion
Jan 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Sep 13, 2023

Study contacts

Qu
Contact
qhyzhl8083@126.com
+8613905316435
Qu
study chair · The First Affiliated Hospital of Shandong First Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion